Drugs / AZD8186
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03218826 | Sep 2018 → Jul 2022 | metastatic malignant neoplasm, metastatic prostate carcinoma, stage IVb bladder cancer, triple-negative breast carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01884285 | Jul 2013 → Mar 2019 | castration-resistant prostate carcinoma, non-small cell squamous lung carcinoma, triple-negative breast carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04001569 | May 2019 → Dec 2021 | gastric cancer | Seoul National University Bundang Hospital | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD8186 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01884285 ↗ |
| Action | Inhibit | “a small molecule inhibitor of PI3Kβ and PI3Kδ” PMID 40939237 ↗ Sep 20252“PI3-kinase p110-delta subunit inhibitor” CHEMBL3408248 ↗ “PI3-kinase p110-beta subunit inhibitor” CHEMBL3408248 ↗ |
| Modality | Small molecule | “a small molecule inhibitor of PI3Kβ and PI3Kδ” PMID 40939237 ↗ Sep 2025 |
| Route | Oral | “AZD8186 administered orally” NCT01884285 ↗ |
| Target | PIK3CB | “PI3-kinase p110-beta subunit inhibitor” CHEMBL3408248 ↗ |
| Target | PIK3CD | “PI3-kinase p110-delta subunit inhibitor” CHEMBL3408248 ↗ |